Close Brothers hit by market conditions
Close Brothers, the FTSE 250 banking, securities and asset management firm, has been affected by difficult market conditions for the Securities division.
Close Brothers, the FTSE 250 banking, securities and asset management firm, has been affected by difficult market conditions for the Securities division.
During the first quarter from 1 August 2011 to 31 October the group continued to see good demand for its lending services and delivered another strong performance.
However, the Securities division has been hit by difficult market conditions, with income per bargain at Winterflood substantially lower, reflecting significant volatility and a change in mix driven by lower risk appetite amongst retail investors.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Close Brothers Seydler has also been affected by challenging conditions for its trading businesses and very limited capital markets activity in Germany.
Meanwhile, the loan book increased 5% to £3.6bn at 31 October (31 July 2011: £3.4bn), with particularly good growth in Retail from both premium finance and motor finance.
In a statement the firm said: "Market conditions have affected the Securities division in the first quarter, and remain difficult. However we continue to see a good performance in the Banking division and our businesses remain well positioned."
The share price fell 3.17% to 673p by 13:42.
NR
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published